

ACCESS STATUS OF ELEXACFTOR/TEZACFTOR/IVACFTOR IN EUROPEAN COUNTRIES

This document was developed by Vertex and is shared upon request of CF Europe.

- This table provides an overview of the access status for elexacftor/tezacftor/ivacftor in combination with ivacftor (ETI) in European countries where Vertex is currently active.
- Vertex is fully committed to making our CF medicines available to as many eligible patients as possible around the world, and our teams are working with governments and communities every day to expand access.
- Beyond the countries in this table, including in lower-income countries, we continue to work on pathways to access that promise the fastest route in each country to enable long-term sustainable access to our medicines.

KEY:

Green cells = official reimbursement

= Broad access via exceptional reimbursement, tenders, broad named patient sales

COUNTRY	ETI 2-5 years	ETI 6-11 years	ETI ≥12 years
Albania			
Andorra			
Armenia			
Austria			
Azerbaijan			
Belarus			
Belgium			
Bosnia		Limited access via tender since mid-2022	
Bulgaria			
Croatia			
Cyprus		#	#
Czechia	#		
Denmark			
Estonia			
England			
Finland			
France	EAP		
Georgia			
Germany			
Greece			
Hungary	#	#	#
Iceland		#	#
Ireland			
Italy			

COUNTRY	ETI 2-5 years	ETI 6-11 years	ETI ≥12 years
Israel			
Latvia			
Liechtenstein			
Lithuania			
Luxembourg			
Malta			
Moldova			
Montenegro		Limited access via NPS since early 2023	
Netherlands			
Northern Ireland			
North Macedonia		Broad scale access via NPS since early 2023	
Norway			
Poland			
Portugal			
Russia		Several hundred patients <18 years old access via Circle of Goodness since 2021	
Romania			
Scotland			
Serbia		Limited access via NPS since late 2021	
Slovakia			
Slovenia			
Spain			
Sweden			
Switzerland			
Turkey		Limited access via NPS since late 2021	
Ukraine		Donation pilot program in Lviv & Kiev	
Wales			